Fig. 3.
IFN-α (mean ± SD) in plasma of F1 mice transplanted with C57BL/6 spleen cells and treated daily with MMF (either 120 mg/kg per day [n=4] or 200 mg/kg per day [n=2]) for 7 days. SCT control (n=5) and leukemia control (n=5) are F1 mice transplanted with C57BL/6 spleen cells plus BCL1 cells or BCL1 cells alone, respectively, and which received no further treatment. MMF120 and SCT group were significantly higher than the leukemia control (p<0.001 and p=0.003, respectively).